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Viruses are often thought to have static structure, and they only remodel after the viruses have entered
target cells. Here, we detected a size expansion of virus particles prior to viral entry using cryo-electron
microscopy (cryo-EM) and single molecule ﬂuorescence imaging. HIV expanded both under cell-free
conditions with soluble receptor CD4 (sCD4) targeting the CD4 binding site on the HIV-1 envelope
protein (Env) and when HIV binds to receptor on cellular membrane. We have shown that the HIV Env is
needed to facilitate receptor induced virus size expansions, showing that the ‘lynchpin’ for size expan-
sion is highly speciﬁc. We demonstrate that the size expansion required maturation of HIV and an
internal capsid core with wild type stability, suggesting that different HIV compartments are linked and
are involved in remodelling. Our work reveals a previously unknown event in HIV entry, and we propose
that this pre-entry priming process enables HIV particles to facilitate the subsequent steps in infection.
& 2015 Elsevier Inc. All rights reserved.Introduction
Cell-free infectious viruses are ultramicroscopic infectious
agents that are often viewed as being metabolically inert and static
in structure, as viruses can only replicate within cells of living
hosts. Human immunodeﬁciency virus (HIV) particles have elec-
tron dense cone-shaped cores, and are pleomorphic in size, with
diameters that range between 100 nm and 200 nm (Briggs et al.,
2003). The interactions amongst HIV envelope (Env) proteins,
cellular receptor CD4 and co-receptors (CXCR4 or CCR5) during
entry are well documented (Wilen et al., 2012), and a series of
structural reorganisations of the viral envelope proteins and the
cellular receptors must follow to facilitate membrane fusion and
viral entry (Wilen et al., 2012). It is currently unknown whether
structural reorganisation would occur within the internal com-
partments of HIV prior to entry to facilitate infection. Observationsoria 3216, Australia.
.mak@deakin.edu.au (J. Mak).
.with the herpes virus system suggest that receptor engagement of
pre-entry viruses may alter the internal capsid core by releasing
the viral tegument protein from the capsid shell (Meckes and
Wills, 2008).
The combination of the miniature- and the pleomorphic-nature
of HIV (Briggs et al., 2003; Benjamin et al., 2005), and the resolution
limits of conventional ﬂuorescence microscopy techniques (Muller
and Heilemann, 2013; Chojnacki and Muller, 2013) have made it
difﬁcult to discern whether any nano-scale internal structural re-
organisation may exist at the pre-entry step of HIV infection. Recent
applications of state-of-the-art imaging and ﬂuorescent probing
techniques have revealed previously unattainable details of HIV
replication, such as the detection of surface HIV Env trimer redis-
tribution during virus maturation (Chojnacki et al., 2012), the
mechanism of tetherin-mediated HIV restriction (Lehmann et al.,
2011), the assembly of HIV Gag and Pol proteins (Van Engelenburg
et al., 2014; Gunzenhauser et al., 2012; Bharat et al., 2014; Schur
et al., 2015; Lelek et al., 2012, 2014), the recruitment of HIV Env and
ESCRT during viral assembly (Van Engelenburg et al., 2014; Muranyi
et al., 2013; Prescher et al., 2015), and the structural details of HIV
S. Pham et al. / Virology 486 (2015) 121–133122Env at the early stages of infection (Bartesaghi et al., 2013; Lyumkis
et al., 2013; Munro et al., 2014).
In the current work, we have used: (1) three dimensional (3D)
structural reconstruction from cryo-electron microscopy (EM)
tomography; (2) two dimensional (2D) projection images from
cryo-EM; and (3) cluster distributions of protein localisations
recorded with direct stochastic optical reconstruction microscopy
(dSTORM) super-resolution ﬂuorescent imaging; to show that cell-
free HIV underwent size expansion upon receptor engagement
with soluble CD4 and when HIV binds to cellular membrane CD4
receptor during infection. Our data showed that both the outer
parameters of viral particles and the internal viral core expanded
as detected by cryo-EM and dSTORM analyses. Further, expansion
was highly speciﬁc and required the engagement of the CD4
binding sites on the HIV Env. The cryo-EM virus size estimations of
untreated and soluble CD4 treated HIV were recorded (blinded,
and with independent operators) using either pairwise analysis
and/or with multiple batches of viruses to ensure that the pleo-
morphic size of HIV was not a confounding factor. We have also
demonstrated that blocking virus maturation or cross-linking of
capsid proteins within the viral core prevents virus particle size
expansions upon receptor engagement. Our dSTORM super-
resolution ﬂuorescent imaging data on the early steps of HIV
infection in T cells provided evidence that these receptor
engagement mediated virus size expansions occur at the pre-entry
stage of HIV infection.Results
Cryo-EM tomograms demonstrate that soluble CD4 caused cell-free
HIV to expand
Using dSTORM super-resolution ﬂuorescent imaging analysis,
we previously reported that the clusters of both matrix (MA) and
capsid (CA) proteins associated with HIV particles undergo sig-
niﬁcant redistribution after infection (Pereira et al., 2012). To
independently assess whether the engagement of the primary
receptor CD4 with HIV is sufﬁcient to induce size expansion, we
compared the sizes of both the viral exterior (matrix protein lat-
tice) and the internal capsid core in cell-free viruses before and
after treatment with soluble CD4 (sCD4) receptor. Both high
(500 μg/ml) and low (50 μg/ml) concentrations of sCD4 were used
to mimic the sCD4 suppressive concentration (Groenink et al.,
1995). Blinded- pairwise-analyses were carried out with multiple
operators to ensure impartiality.
In general, cryo-EM tomography is the predominant technique to
determine the exact size of HIV-1 particles over conventional nega-
tive contrast EM imaging (Briggs et al., 2003; Benjamin et al., 2005;
Subramaniam et al., 2007). Virus particles were identiﬁed in EM
based on the presence of internal electron dense core like structure.
Images of cryo-electron tomography (cryo-ET) tilt series were col-
lected with 2° increment, and 3D re-constructions were performed to
obtain structural models of viral particles (for the principles of cryo-
ET, see Baumeister and Steven (2000)). By scanning through structure
of various reconstructed models of partial HIV particles (that has a
thickness ranging from 15 nm to 50 nm, with a slice thickness
increment of 1.37 nm), the 1.37 nm slice with the largest area was
assigned as the ‘centre slice’ of the virus. Most HIV particles are
ellipsoid and deviate from a perfect sphere; however, diameter is
often used as a reference to estimate the size of HIV particles. Here,
diameters of virus from 3D cryo-ET data were estimated by taking the
average of the distance between two perpendicular axes from the
‘centre slice’.
Multiple batches of HIV were treated with low (50 μg/ml) or
high (500 μg/ml) concentrations of sCD4 for independent-,blinded-, pairwise-diameter and -volumetric analyses (Figs. 1, 2,
S1). Mean matrix (MA) diameter difference was detected when
high (Fig. 1C and D) concentration of sCD4 was used to treat HIV.
3D cryo-ET reconstruction showed that cell-free HIV had a mean
diameter of 124 nm (SEM73.2 nm), which signiﬁcantly increased
(Po0.01) to 134 nm (SEM72.5 nm) after incubation with high
concentrations of soluble CD4 (Fig. 1C and D).
As cryo-ET 3D reconstruction was not feasible for large
amounts of ‘full volume’ virus particles, we compared the volumes
within the MA lattice and the capsid (CA) core before and after
sCD4 treatment using the 15 nm thick central sections (partial
virus volume) of the cryo-ET reconstructions (Figs. 1E–H, 2). A
signiﬁcant size difference of central MA volume of 33% (Po0.01)
was detected when the viruses were treated with high con-
centrations (500 μg/ml) of sCD4 (Fig. 2A and B). Likewise, a sig-
niﬁcant volume increase of 26% was detected with the 15 nm thick
central capsid slice (Fig. 2C and D). Treatment of HIV with low
concentrations of sCD4 (50 μg/ml) did not yield signiﬁcant chan-
ges in diameter (Fig. 1A and B) or 15 nm central volume of the
matrix (Fig. 2E and F), but a signiﬁcant increase within the 15 nm
central volume of capsid was detectable (Fig. 2G and H).
CD4 receptor mediated pre-entry virus size expansion is supported by
2D cryo-EM projection and dSTORM super-resolution ﬂuorescence
image analyses
As HIV is pleomorphic, the low throughput nature of cryo-EM
tomography limits the number of conditions that can be sampled
to dissect the biological details of this pre-entry HIV Env and CD4
receptor interaction. We therefore examined whether alternative
and more rapid procedures could be used as independent tool to
validate that soluble receptor engagement induced virus size
expansion. Six batches of viruses and nearly 1500 HIV particles of
cryo-EM 2D projections (Fig. 3A and B) were used for independent
pairwise, blinded virus diameter estimations (Fig. 3A and E). Dia-
meters were calculated as the average distance between two
perpendicular axes of the 2D cryo-EM projection images. All six
batches of viruses consistently showed an increase of virus dia-
meter upon sCD4 treatment, which increased from 122.6 nm
(SEM72.4 nm) to 133.8 nm (SEM72.3 nm) (Fig. 3C and D).
dSTORM super-resolution imaging was also used to indepen-
dently assess whether virus-associated MA and CA molecules
redistribute upon receptor engagement. The locations of viral
proteins (MA and CA) were estimated using appropriate primary
anti-viral protein antibodies and corresponding species-speciﬁc
secondary antibodies that are tagged with dSTORM compatible
ﬂuorophores. A localisation precision of 20 nm resolutions was
achieved with dSTORM (Fig. 4). Virus particle-associated GFP-Vpr
was used as a locator to identify true virus-associated MA or CA
proteins from background (Fig. 4A and B). Gaussian ﬁtting model,
cluster detection and alignment were used to determine the
morphological features and the projected dimensions of the virus-
associated MA and CA clusters (Fig. 4C and G). Repeated analyses
showed that both the cluster areas of virus-associated MA and CA
molecules have increased signiﬁcantly upon sCD4 treatments
(Fig. 5A and F), supporting the notion that cell-free HIV underwent
size expansion upon sCD4 engagement.
dSTORM comparison between (1) the newly formed HIV from
infected Jurkat cells; and (2) HIV particles that have been arrested
at the early stages of infection using CXCR4 co-receptor blocker
AMD3100 (Donzella et al., 1998) also revealed an increase of
the clustering areas of MA molecules just prior to virus entry
(Fig. 5G–I), showing that the size expansion of HIV also occurs in
natural infection process prior to virus entry.
Although both cryo-EM 2D and dSTORM analyses are less well
suited to estimate the true dimensions of the virus particles
P = 0.4
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Fig. 1. Cryo-EM tomograms illustrate soluble CD4 can cause cell-free HIV to have an increase in matrix diameter. Low (50 μg/ml) and high (500 μg/ml) concentrations of
sCD4 were used for treatment analyses in (A–B) and (C–D), respectively. (A and C) Mean matrix diameters from three independent sets of cryo-EM tomogram recon-
structions were compared in a pairwise- and blinded-fashion. By scanning through each of the 1.37 nm thick cryo-EM tomogram slice, the one with the greatest area was
assayed as the central slice of the virus. The MA diameter was estimated based on the average length of the two longest perpendicular axes on the central slice. (B and D)
Cumulative percentage of viruses with indicated or larger MA diameters of untreated HIV (blue) and of sCD4 treated HIV (red) were presented. (E–H) The 15 nm thick central
portions of the tomogram-reconstructed models were selected for volume comparison. The thickness ‘15 nm’ was arbitrary selected to maximise the number of recon-
structed models available for comparison. (E and G) Examples of cryo-EM images from cryo-EM tomogram of untreated-HIV (E) and sCD4 treated-HIV (G) were presented.
(Fand H) Examples of reconstructed models from cryo-EM tomogram of untreated-HIV (F) and sCD4 treated-HIV (H) were presented. n Values are number of virus particles
used in each arm of the pairwise-, blinded-comparisons. Statistical analyses were carried out using two-way ANOVA. * is Po0.05; ** is Po0.01; *** is Po0.001. Error bars are
standard error of the mean.
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Fig. 2. Cryo-EM tomograms illustrate soluble CD4 can cause cell-free HIV to have an expanded matrix and capsid volume. High (500 μg/ml) and low (50 μg/ml) con-
centrations of sCD4 were used for treatment analyses in (A–D) and (E–H), respectively. Multiple sets of cryo-EM tomogram reconstructions were compared in a pairwise-
and blinded-fashion. By scanning through each of the 1.37 nm thick cryo-EM tomogram slice, the one with the greatest area was assayed as the central slice of the virus. The
15 nm thick central portions of the tomogram-reconstructed models were selected for volume comparison. The thickness ‘15 nm’ was arbitrary selected to maximise the
number of reconstructed models available for comparison. (A and E) The MA volumes from different sets and batches of HIV were compared. (B and F) Cumulative
percentage of viruses with the indicated or higher MA volumes of untreated HIV (blue) and of sCD4 treated HIV (red) were presented. C&G. The CA volumes from different
sets and batches of HIV were compared. (D and H) Cumulative percentage of viruses with the indicated or higher CA volumes of untreated HIV (blue) and of sCD4 treated HIV
(red) were presented. n values are number of virus particles used in each arm of the pairwise-, blinded-comparisons. Statistical analyses were carried out using two-way
ANOVA. * is Po0.05; ** is Po0.01; *** is Po0.001. Error bars are standard error of the mean.
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Fig. 3. 2D cryo-EM projections conﬁrm sCD4 treatments induce HIV to expand. (A and B) Examples of 2D cryo-EM projections images used for virus MA diameter esti-
mations. (C) Mean matrix diameters from six independent sets of 2D cryo-EM projections were compared in a pairwise- and blinded-fashion. The MA diameter was
estimated based on the average length of the two longest perpendicular axes of the virus particles. (D) Cumulative percentage of viruses with indicated or larger MA
diameters from untreated HIV (blue) and from sCD4 treated HIV (red) of the 2D cryo-EM projections data were presented. (E) Mean MA diameters comparisons from 6 sets of
cell-free HIV that have been untreated vs sCD4 treated (500 μg/mL). n Values are number of virus particles used in each arm of the pairwise-, blinded-comparisons. Statistical
analyses were carried out using two-way ANOVA (C). Internal pair statistical analyses were done with two-tailed unpaired t-test (E). * is Po0.05; ** is Po0.01; *** is
Po0.001. Error bars show standard error of the mean (D).
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conﬁrmed that soluble CD4 induces HIV size expansion of both the
MA shell and the CA core portions of the viruses.Engagement of CD4 binding site in HIV Env is the lynchpin of virus
size expansion
Next, we used an envelope negative HIV (Env []) to assess the
speciﬁcity of the receptor-mediated size expansion of HIV. We
performed independent, pairwise, blinded assessment of nearly
650 virus particles from different batches of HIV in four different
sets of experiments with two different concentrations of sCD4
(50 μg/ml and 500 μg/ml). Our data showed that there were no
signiﬁcant differences on the diameter of Env [] HIV particles
before and after sCD4 treatment (Fig. 6). These data provided
evidence that the sCD4 receptor induced size expansion was
speciﬁc and that the engagement of CD4 binding site on the HIVenvelope acted as the lynchpin of virus expansion prior to
virus entry.
CD4 receptor mediated virus size expansion requires multiple viral
components
It was recently demonstrated that viral protease-induced
maturation of HIV-1 involves re-positioning of Env trimers from
random distribution on the surface of immature HIV-1 to clus-
tering of Env proteins on the membrane of mature viruses (Choj-
nacki et al., 2012). As this protein clustering is important for Env
binding to CD4 (Chojnacki et al., 2012), we asked whether there is
a mechanistic link between Env clustering and the observed CD4
engagement-induced virus remodelling. Using a protease-
defective point mutant (PR [-], immature HIV) that locks HIV in
its immature state, 2D cryo-EM projection analyses showed that
sCD4 treatment, even at high sCD4 concentration (500 μg/ml), did
not lead to size expansion of HIV PR [] (Figs. 7A and B, S2).
Fig. 4. dSTORM morphology analysis of protein clusters of cell-free HIV particles. (A) Reconstructed dSTORM image of individual immuno-labelled capsid (CA) localisations
(red dots). Individual GFP spots of GFP-Vpr (green dots) were identiﬁed using a Gaussian ﬁtting model. (B) Selection of CA clusters for inclusion in morphological analysis
(highlighted area from A). Clusters of CA localizations outside a 250 nm radius of a GFP position and CA cluster sizes with a radius 4250 nm were excluded (red dotted
square). Further, clusters that contain less than 500 localizations were also excluded as few localisation per cluster reduces the accuracy of the dSTORM size measurements.
Importantly, only clusters that fulﬁl both sets of criteria (size/density and GFP-Vpr association) were included in the analysis (blue square). (C–F) Cluster detection and
alignment. Clusters were identiﬁed with incremental circles until the density of localisation in a ring deﬁned by two successive circles is less than 0.5% of the density from
the previous ring. Principle component analysis was used to identify the long axis within individual CA clusters (D) and aligned to north–south orientation (E). (F) CA clusters
were converted to normalised density maps, shown with in a heat map representation. (G) Binary map of a CA clusters, obtained by applying a FWHM threshold to density
maps. Morphological parameters such as area, length of the long and short axes were extracted for individual CA cluster from binary maps.
S. Pham et al. / Virology 486 (2015) 121–133126Hence, either the virus maturation process and/or the clustering of
Env is a pre-requisite for HIV to undergo CD4-induced virus size
expansion.
One of the hallmarks of HIV-1 maturation is the formation of
the cone-shaped core, through interaction amongst capsid mole-
cules (Ganser-Pornillos et al., 2007; Pornillos et al., 2011; Zhao et
al., 2013). It has been estimated that the broad base of the HIV-1
core is within 11 nm from the viral lipid membrane (Benjamin et
al., 2005) while the narrow ends of the core are in close contact
with the inner viral membranes (Briggs et al., 2006). Given that
the central 15 nm thick 3D cryo-EM reconstructed capsid volume
(Fig. 2C–D,G–H) and dSTORM CA cluster area increased upon
receptor engagement (Fig. 5C–D,F), we asked whether the size
expansion of the virus would be affected by the stability of the
capsid core. Using mutant HIV with CA A204C that has a hyper-
stable core and are non-infectious (Zhao et al., 2013), 2D cryo-EM
projection data (Figs. 7C and D and S2), dSTORM data of MA area
clusters (Figs. 7E and F and S2) and CA clusters (Figs. 7G and H and
S2) showed that stabilising the virus core impaired the ability of
sCD4 to induce virus size expansion and HIV to infect target cells.
These data suggest that size expansion involves the participation
of different compartments of virus particle, including the internal
viral core. Importantly, as a number of non-infectious virus
mutants (i.e. Env deleted viruses, immature HIV and hyperstable
core A204C mutant) are also incapable to expand after sCD4
treatment, these data suggest this receptor mediated size expan-
sion is likely to be an important biological process.Discussion
Meckes and Wills have previously reported that an ‘outside-in’
signal can be sent through virus membrane during receptorengagement. The interactions of herpes simplex virus with its
cellular receptor can lead to internal release of the viral tegument
proteins from the viral capsid complex (Meckes and Wills, 2008).
In agreement with the observations in Herpes simplex virus
(Meckes and Wills, 2008), our current study provides direct evi-
dence that cell-free HIV is able to receive an external trigger (here
engagement of the CD4 binding site on Env) to elicit nano-scale
virus structural reorganisation. Our evidence are as follows:
(1) soluble CD4-engagement can cause cell-free HIV to expand;
(2) virus size expansion is highly speciﬁc and does not occur with
Env [] HIV mutant; and (3) CD4-mediated virus expansion is
dependent on viral replication processes, such as the maturation of
HIV and the wild type stability of virus core. Together, we propose
that HIV-1 undergoes a pre-entry priming process, which may
enable viral particles to facilitate subsequent infection process.
We present data using three independent techniques; multiple
batches of viruses; and pairwise, blinded analyses to demonstrate
that CD4 receptor engagement induced virus size expansion. Due
to the inherent but distinct limitations of these different techni-
ques, it is not expected these approaches would necessarily yield
identical estimated values regarding the size of HIV. Amongst
these approaches, the estimations from 3D cryo-ET reconstruction
are likely to be the closest to the true HIV particles. 3D cryo-ET
analyses showed that the mean MA diameter of the particles
expanded from 124 nm (SEM73.2 nm) to 134 nm (SEM72.5 nm)
and the volume enclosed by the 15 nm central capsid expanded by
26% after incubation with high concentrations of soluble CD4. The
expansion of the matrix lattice measured here may require an
expansion of the lipid envelop surrounding the matrix lattice,
raising question about the involvement of lipids and membrane-
associated proteins in such process.
Unlike host cells, viruses do not have the capacity to synthesise
lipids, raising the question of how the virus membrane compensates
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Fig. 5. dSTORM super-resolution analyses detect viral protein cluster size expansion upon virus and CD4 receptor engagement. The mean dSTORM estimated areas of MA
(A) and CA (C) protein molecule clusters from different sets and batches of cell-free HIV were compared. (B and D) Cumulative percentage of viruses with indicated or higher
dSTORM estimated areas of MA (B) and CA (D) protein molecule clusters of untreated HIV (blue) and from sCD4 treated HIV (red) were presented. The length of antibodies
used in dSTORM overestimated the actual size of protein clusters. (E) Mean dSTORM estimated MA area comparisons from 2 sets of cell-free HIV that have been untreated vs
sCD4 treated (500 μg/mL). (F) Mean dSTORM estimated CA area comparisons from 2 sets of cell-free HIV that have been untreated vs sCD4 treated (500 μg/mL); (G) The
dSTROM estimated areas of MA protein molecule clusters from different sets and batches of newly formed HIV that are being released from Jurkat cells (blue) and pre-entry
HIV that are arrested on the cell surface via CXCR4 co-receptor blocker AMD3100 (red). (H) Cumulative percentage of viruses with indicated or higher dSTORM estimated
areas of MA protein molecule clusters of newly released HIV (blue) and pre-entry AMD3100 membrane arrested HIV (red) were presented. (I) Mean dSTORM estimated MA
area comparisons from 2 sets of: (1) Jurkat cellular membrane-associated newly released HIV vs (2) Jurkat cellular membrane-associated pre-entry arrested HIV. n Values are
number of virus particles used in each arm of the pairwise-, blinded-comparisons. Statistical analyses were carried out using two-way ANOVA (A, C and G). Internal pair
statistical analyses were done with two-tailed unpaired t-test (E, F, I). * is Po0.05; ** is Po0.01; *** is Po0.001. Error bars show standard deviation (B, D, H).
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S. Pham et al. / Virology 486 (2015) 121–133128for this estimated increase in surface area upon CD4 engagement. One
potential explanation is that as HIV-1 contains tightly packed lipid
molecules in the forms of rafts microdomains (Brugger et al., 2006), a
repacking (possibly via phase transition) of lipid molecules during viral
entry may account for the increase in membrane surface area during
receptor engagement, a process that is analogous to the rearrange-
ment of cholesterol–sphingolipid enriched rafts microdomains during
cellular signalling events (Simons and Gerl, 2010). It is however
important to acknowledge that it is currently unknown how different
virus-associated lipid rafts components are packed in an infectious HIV
particle (Brugger et al., 2006), and whether both rafts and non-rafts
‘nano’-domains co-exist within the membrane of these 100–200 nm
virus particles. Recent work has implicated that HIV may enter the
target cell at the juncture of liquid ordered-rafts domain and liquid
disordered-non-rafts domains to promote fusion (Yang et al., 2015),and it is tempting to speculate that both the rafts and non-rafts ‘nano’-
domains may co-exist in HIV particles. The clustering of HIV Env
protein during virus maturation (Chojnacki et al., 2012) would suggest
that the virus lipid membrane during viral assembly is likely to be
sufﬁciently ﬂuid that can support the movement of proteins and
perhaps repacking of lipid molecules. More sophisticated tools are
needed to deﬁne the dynamics of lipid and protein movement within
the viral membrane.
Our data rule out both the pleomorphic nature of HIV and the
size variation amongst different batches of HIV as contributors to
the observed size expansion of HIV. Given the lack of virus size
increase in our Env negative HIV, immature HIV, and hyperstable
core HIV mutant, we can also rule out that experimental condi-
tions (such as detergent used in dSTORM analysis and the
osmolality of buffer) bias our data. The requirement of HIV
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Fig. 7. CD4 receptor mediated virus size expansion requires multiple viral replication processes. High (500 μg/ml) concentrations of sCD4 were used for treatment. Mean
matrix diameters (A and C) and their cumulative frequencies (B and D) from independent sets of 2D cryo-EM projections of cell-free PR [] immature HIV (A and B) or cell-
free hyperstable core HIV A204C (C and D) were compared in blinded analyses. The dSTORM estimated areas of MA (E and F) and CA (G and H) protein clusters of cell-free
hyperstable core HIV A204C before and after sCD4 treatment were also compared. No size increase has been detected before and after sCD4 treatment using either 2D-
cryoEM projection analyses or dSTORM protein molecule clustering. n Values are number of virus particles used in each arm of the pairwise-, blinded-comparisons. Statistical
analyses were carried out using two-way ANOVA. Error bars show standard deviation.
S. Pham et al. / Virology 486 (2015) 121–133 129envelope to support sCD4 mediated virus size expansion argues
for the speciﬁcity of the process, indicating that CD4–Env
engagement is the lynchpin of this virus size expansion process.
Conceptually, the CD4–Env interaction induced changes in internal
virus structure appear to be similar to cellular signalling events. It
is currently unclear whether such a process relates to the classicalsignalling events in eukaryotic cells and/or involves virus co-
packaged host derived signalling molecules (Chertova et al., 2006).
The most likely role of this receptor engagement-induced size
expansion of HIV (which is similar to the release of tegument
proteins in the case of Herpes simplex virus; Meckes and Wills,
2008) is to prime the virus to commit to the next phase of the
S. Pham et al. / Virology 486 (2015) 121–133130infection process. As such commitment may expose vulnerable
and highly conserved epitopes of the virus and hence may elicit a
strong immune response, one would predict that this pre-entry
priming event is initiated in a highly speciﬁc and timely manner to
avoid pre-mature exposure of these epitopes. Interestingly, sCD4
that prematurely induces such priming events also induces strong
antiviral activities. Madani et al. (2014) reported that a small
molecule CD4-mimetics are able to sensitise HIV-1 to neutraliza-
tion, while Munro et al. (2014) observed that CD4 engagement
leads to remodelling of HIV Env proteins from a dynamic state to a
more stabilised conformation. Huang et al. (2014) have observed
that receptor engagement of virus particles leads to a strong
binding of broadly neutralising antibody 35O22, and suggested
that this was achieved by raising the Env spike 15 Å away from the
viral membrane after CD4 engagement (Huang et al., 2014).
Although these studies focus primarily on the rearrangement of
Env on the membrane surface upon CD4 engagement and struc-
tural rearrangement of the Env protein itself is sufﬁcient to expose
the Achille’s heel of HIV for immune attack, our data however
provide direct physical evidence that these pre-entry priming
structural rearrangements also extend to the internal virus archi-
tecture. These data are consistent with each other that the pre-
entry priming of HIV particles via the unique properties of CD4–
Env engagement can lead to remodelling across many viral com-
partments of HIV, highlighting the existence of a previously un-
appreciated process in HIV entry.
The ﬁnding that a speciﬁc trigger induces HIV size expansion
and requires multiple HIV compartments suggests that virus
remodelling is similar to changes seen in metastable structures.
Indeed, viruses can be described as being locked in metastable
conformations and poised to undergo major conformational
changes during assembly and entry (Steven et al., 2005; Marsh and
Helenius, 2006). Our data suggest that HIV is a metastable virus
prior to cell entry, which enables remodelling of the entire virus.
Recent reports have shown that retroviral capsid can assume dif-
ferent hexamer conformations (Gres et al., 2015; Obal et al., 2015),
suggesting different hexamers within the HIV capsid core may
have different packing. Given these new ﬁndings, a possible
explanation for our observations would be that sCD4 engagement
of HIV Env might have shifted the equilibrium of the HIV CA
hexamer packing from having various types of CA hexamers to
common CA hexamer packing that resulted in a larger capsid core.
However, sophisticated molecular dynamics analyses (Zhao et al.,
2013) are needed to determine whether cell free HIV capsid core is
indeed able to ‘breathe’ as seen with the West Nile virus envelope
(Dowd et al., 2011) and/or the reversible opening of Hepatitis B
virus core (Rabe et al., 2009).
Our data uncover a previously unknown process of HIV entry.
This phenomenon of pre-entry priming of HIV upon receptor
engagement may represent a general principle for other enveloped
viruses to prime metastable cell-free virus in order to commit to
the next phase of viral infection. Understanding the details of
these priming events may lend to a fresh perspective in the
development of novel HIV therapeutics.Materials and methods
Production of HIV-1 particles and infections
The pNL4-3 proviral DNA contains the infectious molecular
clone of HIV. Mutants (HIV-1 PR[-], HIV-A204C) are derivatives of
the pNL4-3 (Chojnacki et al., 2012; Zhao et al., 2013; Gottlinger et
al., 1989; Forshey et al., 2002). All HIV-1 particles were produced
by poly(ethylenimine) (PEI; Polysciences Inc., PA, USA) transfection
of HEK 293T cells (ATCC, USA) with corresponding proviral DNAand GFP-Vpr plasmid to generate GFP-Vpr-labelled HIV (Pereira et
al., 2012). Forty hours post-transfection, viral particles were pur-
iﬁed, concentrated and quantiﬁed, as described previously (Pereira
et al., 2012). Brieﬂy, supernatant from 293 T cells was ﬁltered with
0.2 μm Minisart Syringe Filter (Sartorius, Germany). Viral particles
were concentrated by ultracentrifugation, either directly or
through a 20% sucrose cushion, at 100,000 g for 1 h at 4 °C using
an L-90 ultracentrifuge (SW 41 rotor, Beckman, USA). Virus pellets
were resuspended in 1 phosphate buffered saline and quantiﬁed
using a HIV-1 antigen (p24 CA) micro enzyme-linked immuno-
sorbent assay (ELISA) (Vironostika, Boxtel, The Netherlands). After
quantiﬁcation, virus samples were diluted with phosphate buf-
fered saline to a concentration of 10 ng/ml, aliquotted and stored at
80 °C. In all assays, single aliquots were defrosted at room
temperature for 10 min directly prior to the experiment, thus each
virus solution underwent a single freeze–thaw cycle. For these
experiments three separate batches of virus were prepared, with
multiple assays run. For each individual technique described
below, assays using virus from at least two independent batches
were used.
Infection of Jurkat T cells
Infections were performed on T cell line as described previously
(Pereira et al., 2012). Brieﬂy, for non-synchronised infection, Jurkat
cells (NIH AIDS Reagent Program, USA) were mixed with HIV-1
particles (normalised to 1000 ng of p24 per million cells) followed
by spinoculation at 17 °C for 2 h at 1200 g. A concentration of
0.2 mg/mL AMD3100 was added to uninfected Jurkat cells at 37 °C
incubation for 20 min prior to spinoculation with HIV-1 particles.
Infections were then carried on for 2 h at 37 °C incubation (5%
CO2). The cells were washed three times with PBS to remove
unbound virus. Adding paraformaldehyde to a ﬁnal concentration
of 4% stopped the infection. Cells were then stored on ice for
immediate dSTORM analysis.
Treatment of cell-free viruses with sCD4
sCD4 was produced by Progenics Pharmaceutical, Inc. and
obtained through the NIH AIDS reagent program. Treatment con-
centration of sCD4 was with either 50 μg/mL or 500 μg/mL against
5000 ng p24/mL virus (as determined by p24 concentration),
which was selected as closest to the suppressive concentration
used in an in vitro tissue culture infection experiment. More
speciﬁcally, for each treatment with 50 μg/mL of sCD4, 50 μL of
viral suspension (normalised to 10,000 ng of p24 per mL) was
incubated with 50 μL of sCD4 (100 μg/mL). For all treated samples
a buffer treated control was run concurrent to sCD4 treatment and
from the same aliquot of virus. Incubation was for a minimum of
2 h at 37 °C (5% CO2). Adding paraformaldehyde to a ﬁnal con-
centration of 4% stopped the incubation and inactivated the buffer
and sCD4 treated virus. When high sCD4 concentrations
(500 μg/mL) of sCD4 were used on WT or mutant HIV-1 to
demonstrate the speciﬁcity of the event, a lower virus con-
centration was used. After the reaction was stopped and the virus
inactivated, samples were aliquoted and stored at 80 °C.
Cryo-EM specimen preparation and data collection
Paired aliquots of sCD4 and buffer treated HIV-1 were thawed at
room temperature for 10 min. Cell-free sample (6 μL) was applied
to the top surface of a glow discharged, perforated carbon ﬁlm on a
hexagonal mesh EM gold sample grid (CF-MH-2Au-50, Protochips,
USA), followed by application of 2 μL of 10 nm colloidal gold solu-
tion (Sigma Aldrich, Australia). Samples were blotted for 30 s at
above 80% humidity, from the reverse side with ﬁlter paper before
S. Pham et al. / Virology 486 (2015) 121–133 131immersion freezing in liquid ethane using a semi-automated
plunging apparatus (Cryoplunge™3 – Cp3, Gatan, USA). Low dose
(35–50 e/Å2) cryo-EM micrographs were captured on either an
Ultrascan 1000 2k2k CCD (charge-coupled device) camera ﬁtted
to a JEOL 1400 microscope operated at 120 kV and 15,000 mag-
niﬁcation, corresponding to a pixel size of 0.69 nm, or using an
Utrascan 1000 (Gatan, Pleasanton, CA) on an FEI Tecnai F30
microscope (FEI, Eindhoven) operated at 300 kV and 15,000
magniﬁcation, corresponding to a pixel size of 0.71 nm.
Cryo-EM tomographic reconstruction
Cryo-ET tilt series of cell-free HIV-1 particles in speciﬁc con-
ditions were collected on the same equipment by tilting the spe-
cimen from 65° to þ65° at 2° increments, with a total dose of
approximately (3500 e/nm2) and a defocus value of 5 mm. Three-
dimensional reconstructions were computed using the 3D feature-
tracking algorithm implemented in JEOL Composer software.
EM image processing
Image reﬁnement was carried out using Normalize Local Con-
trast (Integral Image Filter) and Anisotropic Diffusion 2D imple-
mented within Fiji (a bundled version of ImageJ) (Rasband and
Image, 1997). Virus particle size was determined manually using
ImageJ by two independent analysts. Particle average diameter
was determined by manually deﬁning the length and width of
each particle (analyst 1) or by deﬁning the perimeter and having
length, width and average diameter computed by Image J (analyst
2). All samples were blinded prior to analysis by analyst 2. For
segmentation and 3D rendering, a contrast normalised recon-
structed volume was processed using ImageJ. The 3D cryo-EM
tomographs were analysed using IMOD (Regents of the University
of Colorado) (Kremer et al., 1996; Mastronarde, 1997), with the
volume computed by IMOD after the matrix and capsid perimeters
were manually deﬁned. Statistical signiﬁcance was determined as
described below.
Immunoﬂuorescence staining
Cells and viruses were ﬁxed with 4% paraformaldehyde, as
described previously and stored either on ice (cells) or frozen in
aliquots (virus). Immediately before the assay, samples were per-
meabilized with a solution of Triton-X 1% in PBS. Afterwards the
samples were stained sequentially with a 1st and 2nd antibody.
The ﬁrst antibody was either mouse anti-matrix (SVM-33) anti-
body MH-SVM33C9, ATCC, Manassas, VA (Akzo Nobel N.V.) or
mouse anti-capsid (AG3.0) antibody (obtained through the AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH from J. Allan) (Simm et al., 1995). The secondary antibody was
from donkey speciﬁc to mouse F(ab’)2, conjugated to Dylight 649
(715496150, Jackson ImmunoResearch). To perform dSTORM, we
used an oxygen-scavenging buffer11 solution (25 mM HEPES,
25 mM glucose, 5% glycerol, 0.05 mg/ml glucose oxidase and
0.025 mg/ml horseradish peroxidase, supplemented with 20 mM
cysteamine; all from Sigma).
Image acquisition
The principle and instrumentation of dSTORM have been
extensively described previously (van de Linde et al., 2011).
dSTORM acquisition was performed in an oxygen-scavenger buffer
using a total internal reﬂection ﬂuorescence microscope (ELYRA;
Zeiss) with a 100 oil-immersion objective featuring a numerical
aperture of 1.46. Lasers 405 nm and 642 nm were used for acti-
vation and excitation of Dylight 649, respectively. The sampleswere prepared for dSTORM by illuminating with maximum power
of 642 nm at 20 mW for a few seconds to block the Dylight 649 in
a dark triplet state. For the acquisition, 405 nm laser was set in the
range 10–100 mW for activation and 642 nm laser at 15 mW for
excitation. For a single acquisition, 20,000 images of 2525 mm
were recorded with a cooled, electron multiplying charge-coupled
device camera (iXon DU-897D; Andor) using 30 ms for exposure
time. Finally for each dSTORM acquisition, an additional image was
recorded at 488 nm of the same area to identify the position of the
GFP fused to vpr protein. The images were recorded using Zeiss
Zen software (Rossy et al., 2013).
dSTORM data processing and analysis
Processing of the raw images, including molecule detection and
drift correction was carried out with Zeiss Zen 2010D Software
(version 7.0.0.366). After Gaussian and Laplace ﬁltering, events
were judged to have originated from single molecules when
IM46S, where I is the event intensity, M the mean image
intensity and S the standard deviation of image intensity. The
centre of each point-spread function was then calculated by ﬁtting
to a two-dimensional Gaussian distribution. Drift correction was
performed using a method based on triangulation of localisation
data and a piecewise-linear drift model. The x–y position coordi-
nates of each detected spot were stored in a table. Events with
localisation precision worse than 50 nm were discarded (Wil-
liamson et al., 2011). GFP images were analysed with the same
detection method to identify the localisation of the GFP-vpr (Fig.
S2). In Fig. S2g, the green spots represent the detected GFP pro-
teins corresponding to the centre of the point-spread function.
For morphological analysis, the dSTORM pointillist images were
analysed with a Matlab routine. Clusters were detected and mor-
phologically analysed using a method similar to that described by
Lelek et al. (2012). To ensure that each analysed cluster is a gen-
uine HIV particle, ﬁrst we identify the location of the highest
density (which is the centre of the cluster) within a 250 nm radius
of a single GFP localisation. Then starting from the point of max-
imum density as the centre, we drew circles by 10 nm increments,
and calculated the density in each ring deﬁned by two successive
circles. If the calculated densities decreased more than 99.5%,
between successive rings, we stopped the incrementation and the
cluster is identiﬁed (Fig. S2c). Clusters containing less than 500
positions were not included in the analysis; only very dense
clusters were used in order to obtain accurate measurements of
virus sizes. Clusters with larger than 250 nm radius were dis-
carded to ensure that the clusters retained for morphological
analysis were individual clusters and not aggregates of virus par-
ticles (Fig. S2b). Examples of individual selected clusters are
represented in Fig. S2b. The individual clusters were rotated to
align the principal axis using principal component analysis. Next, a
density map was obtained by applying a smoothed 2D histogram,
binning the positions in 500500 pixel grids and convoluting
with a Gaussian function of standard deviation 5 nm. Each cluster
density map was normalised proportionally to the number of
localisations (Fig. S2f). A binary image of each cluster was obtained
after thresholding at full width half maximum (FWHM), and used
to determine the characteristics of the virus particles such as the
area, diameter, width and length.
Each virion can be regarded as a single measurement. On
average, we detected 1000 MA and 1500 CA localizations per
wild-type virus particle. The accuracy of a structure is deﬁned by
the Nyquist–Shannon sampling theorem, which states that one
needs twice as many point localizations (i.e. two-fold over-sam-
pling) for a given resolution (Thompson et al., 2010). With an
average area of 8171 nm2 for MA and o4800 nm2 for CA, the
average distance between localisation is 2.8 nm for MA and
S. Pham et al. / Virology 486 (2015) 121–133132o1.8 nm for CA. This means that the accuracy of our size mea-
surement for each cluster, the Nyquist resolution, is 5.6 nm for
MA and 3.6 nm for CA.
The resolution limit of a structure detected with dSTORM can be
further improved by averaging, in our case by calculating the means,
standard deviations and standard error mean of typically 100–300
individual virus particles per condition, therein lies the statistical
power of dSTORM data. Averaging of dSTORM images of the nuclear
pore complex was recently used to detect differences in distances
between subunits of less than 1 nm (Szymborska et al., 2013).
Statistics
The statistical signiﬁcance between treated and untreated
conditions with the reported sample sets (30-500 data points
per set) were assessed. For all paired samples (buffer treated and
sCD4 or antibody treated), we performed two-tailed unpaired t-
test to compare the means of two unmatched data, derived either
from virus particle diameters (EM) or from the scatter plots
(dSTORM) as well as the cumulative distribution of two groups
(treated and untreated). To statistically analyse multiple replicates,
we used two-way ANOVA, analysing both the treatment effect and
any effects due to variation in viral batches and/or assays. This was
done to remove any bias due to individual virus batches or assays.
For all methods, assays were run with at least 2 independent
batches of virus, and with three replicate assays unless otherwise
stated. All the statistical tests were performed using GraphPad
Software from Prism. The statistical difference was deﬁned as non-
signiﬁcant when p40.05, or statistically signiﬁcant when po0.05
(notation n), po0.01 (notation nn), po0.001 (notation nnn).Acknowledgment
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